When should a baseline and follow‑up transthoracic echocardiogram be obtained for patients receiving doxorubicin?

Echocardiographic Monitoring for Doxorubicin Therapy

All patients receiving doxorubicin require a baseline transthoracic echocardiogram before initiating therapy, with follow-up imaging at 3-month intervals during treatment and symptom-driven thereafter, or at 1-month intervals if cardioprotective medications are initiated. 1

Baseline Echocardiography

• Obtain a high-quality baseline echocardiogram with ejection fraction (EF) measurement before starting doxorubicin in all patients. 1
• Consider using contrast enhancement, 3D imaging, and global longitudinal strain (GLS) imaging when available to improve accuracy and detect subclinical dysfunction. 1
• If baseline EF is <50% or at the institution's lower limit of normal, refer to cardiology before proceeding with anthracycline therapy. 1
• The baseline assessment should identify high-risk patients including those with pre-existing heart disease, diabetes, hyperlipidemia, extremes of age (very young or elderly), female sex, or plans for high-dose anthracycline therapy. 1

During Treatment Surveillance

• Monitor with echocardiography at 3-month intervals during active doxorubicin therapy. 1
• If cardioprotective medications (beta-blockers or ACE inhibitors) are initiated due to EF decline, increase monitoring frequency to 1-month intervals. 1
• Perform additional symptom-driven echocardiography if clinical signs of heart failure develop at any point. 1
• Research data suggest subclinical cardiotoxicity can occur at cumulative doses as low as 244.5 mg/m², well below the traditional 300 mg/m² threshold, supporting early and frequent monitoring. 2

Thresholds for Withholding Therapy

• Withhold doxorubicin if EF drops below 45%. 1
• Consider holding therapy if EF decreases by >10% from baseline, particularly if accompanied by abnormal GLS (>15% relative reduction) or elevated troponin. 1
• These thresholds represent the last resort for therapy modification, as oncologic benefit must be weighed against cardiac risk. 1, 3

Post-Treatment Follow-Up

• Obtain a post-therapy echocardiogram after completing doxorubicin treatment. 1
• Repeat echocardiography at 6 months or 1 year after treatment completion. 1
• If EF remains abnormal on post-treatment imaging, follow ACC/AHA heart failure guidelines for ongoing management. 1
• Long-term surveillance is important as cardiac dysfunction can manifest with delayed onset. 3

Additional Monitoring Considerations

• Incorporate cardiac biomarkers (troponin and BNP) alongside echocardiographic surveillance, though their role in routine monitoring continues to be refined. 1, 3
• The British Society for Echocardiography and British Cardio-Oncology Society have published detailed protocols for standardized acquisition and interpretation of echocardiograms in this population. 4, 5
• Patients receiving doxorubicin combined with immune checkpoint inhibitors face significantly higher rates of cancer therapy-related cardiac dysfunction (38.1% vs. 17.4% with doxorubicin alone) and warrant particularly vigilant monitoring. 6

Common Pitfalls to Avoid

• Do not wait until the traditional cumulative dose threshold of 550 mg/m² to begin surveillance, as cardiac deterioration is detectable at much lower doses. 7
• Do not rely solely on symptoms, as significant subclinical dysfunction (defined as EF drop >10% or EF <55% without heart failure symptoms) occurs in approximately 16.7% of patients and requires early detection for optimal outcomes. 2
• Avoid delaying cardiology consultation in high-risk patients, as early intervention with ACE inhibitors and beta-blockers leads to better LVEF recovery when initiated within 1-2 months of developing left ventricular dysfunction. 3